Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CDK5 | Q00535 | 9/20 | 0.46 |
| ▸ | CDK5R1 | Q15078 | 9/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 6/20 | 0.44 |
| ▸ | CDK2 | P24941 | 6/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CDK1 | P06493 | 2/20 | 0.40 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.35 |
| ▸ | CCND3 | P30281 | 1/20 | 0.35 |
| ▸ | FLT3 | P36888 | 1/20 | 0.35 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30676854 | 1.00 | GRM5 (0.51) | GRM5MAOBCDK5CDK5R1CCNA2 | |
| SCHEMBL929793 | 0.98 | GRM5 (0.50) | GRM5MAOBCDK5CDK5R1CCNA2 | |
| SCHEMBL1819834 | 0.96 | GRM5 (0.47) | GRM5MAOBCDK5CDK5R1CCNA2 | |
| SCHEMBL24383245 | 0.75 | GRM5 (0.33) | GRM5MAOBSMN1; SMN2 | |
| SCHEMBL9954250 | 0.74 | CDK5 (0.46) | GRM5MAOBCDK5CDK5R1CCNA2 | |
| SCHEMBL29564444 | 0.74 | CDK5 (0.46) | GRM5MAOBCDK5CDK5R1CCNA2 | |
| SCHEMBL6234455 | 0.74 | CDK5 (0.46) | GRM5MAOBCDK5CDK5R1CCNA2 | |
| SCHEMBL601423 | 0.74 | NOS3 (0.47) | GRM5MAOBCDK5CDK5R1CCNA2 | |
| SCHEMBL13865788 | 0.74 | CDK5 (0.51) | GRM5MAOBCDK5CDK5R1CCNA2 | |
| SCHEMBL10013082 | 0.74 | CDK5 (0.46) | GRM5MAOBCDK5CDK5R1CCNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117683035-A | Synthesis method of substituted pyrazoloquinazoline derivative | 成都睿智化学研究有限公司 | 2024-03-12 | — | — | CN | claimed |
| US-12522595-B2 | Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2026-01-13 | — | — | US | disclosed |
| WO-2025067126-A1 | PYRIDONE COMPOUNDS AND PREPARATION METHOD THEREFOR, AND APPLICATION | 深圳信立泰药业股份有限公司 | 2025-04-03 | — | — | WO | disclosed |
| CN-117683035-A | Synthesis method of substituted pyrazoloquinazoline derivative | 成都睿智化学研究有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117683035-A | Synthesis method of substituted pyrazoloquinazoline derivative | 成都睿智化学研究有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-117229208-B | Condensed ring compound, preparation method and medical application thereof | 上海泽德曼医药科技有限公司 | 2024-02-23 | — | — | CN | disclosed |
| CN-117229208-A | Condensed ring compound, preparation method and medical application thereof | 上海泽德曼医药科技有限公司 | 2023-12-15 | — | — | CN | disclosed |
| US-11685749-B2 | C26-linked rapamycin analogs as mTOR inhibitors | Revolution Medicines, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220106305-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | BIOGEN MA INC. | 2022-04-07 | — | — | US | disclosed |
| EP-3921316-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | Biogen MA Inc. (US) | 2021-12-15 | — | — | EP | disclosed |
| CN-1486312-A | Pyrazole compounds useful as protein kinase inhibitors | ��̩��˹ҩ��ɷ�����˾ | 2004-03-31 | — | — | CN | disclosed |
| CN-1486310-A | Pyrazole compounds useful as protein kinase inhibitors | ��̩��˹ҩ��ɷ�����˾ | 2004-03-31 | — | — | CN | disclosed |
| CN-1486311-A | Pyrazole compounds useful as protein kinase inhibitors | ��̩��˹ҩ��ɷ�����˾ | 2004-03-31 | — | — | CN | disclosed |
| CN-1102144-C | Noval pyrimidine derivatives and prepn. processes thereof | YUHAN CORP (KR) | 2003-02-26 | — | — | CN | disclosed |
| US-6384224-B2 | FOR THERAPY AND PROPHYLAXIS OF PSYCHOTIC DISORDERS SUCH AS SCHIZOPHRENIA AND OTHER CENTRAL NERVOUS SYSTEM DISEASE | NEUROGEN CORPORATION | 2002-05-07 | — | — | US | disclosed |
| US-20020013317-A1 | Certain 1- (2-naphthyl) and 1- (2- azanaphthyl) -4- (1-phenylmethyl) piperazines; dopamine receptor subtype specific ligands | NEUROGEN CORPORATION | 2002-01-31 | — | — | US | disclosed |
| US-6331629-B1 | TREATMENT OF NEURO-PSYCHOLOGICAL DISORDERS | NEUROGEN CORPORATION | 2001-12-18 | — | — | US | disclosed |
| CN-1283195-A | 1-(2-naphthyl) and 1(2-azanaphthyl)-4-(1-phenylmethyl)piperazines being dopamine D4 receptor subtype ligands | NEUROGEN CORP (US) | 2001-02-07 | — | — | CN | disclosed |
| US-6040448-A | USEFUL FOR TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS SUCH AS SCHIZOPHRENIA AND OTHER CENTRAL NERVOUS SYSTEM DISEASES. | NEUROGEN CORPORATION (US) | 2000-03-21 | — | — | US | disclosed |
| CN-1155281-A | Noval pyrimidine derivatives and prepn. processes thereof | YUHAN CORP (KR) | 1997-07-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685749-B2 | C26-linked rapamycin analogs as mTOR inhibitors | MTOR, RICTOR, RPTOR | GRM5 2788/4885MAOB 4378/4885CDK5 526/4885 |
| US-20220106305-A1 | BICYCLIC ETHER O-GLYCOPROTEIN-2-ACETAMIDO-2-DEOXY-3-D-GLUCOPYRANOSIDASE INHIBITORS | ENGASE, UGGT1, MGAT3 | GRM5 3182/4885MAOB 1012/4885CDK5 4180/4885 |
| US-20020013317-A1 | Certain 1- (2-naphthyl) and 1- (2- azanaphthyl) -4- (1-phenylmethyl) piperazines; dopamine receptor subtype specific ligands | DRD2, DRD4, DRD3 | GRM5 129/4885MAOB 197/4885CDK5 2082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.